TYNDALL JOSEPH A. sold $174K of AXGN

TYNDALL JOSEPH A. sold 3,500 shares of Axogen, Inc. (AXGN) at $49.70 ($0.17M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · TYNDALL JOSEPH A.
Published Sep 4, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AXGN
Neutral
medium confidence
Mentioned
$AXGN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXGNNeutralLow
01

Why it matters

The sale is modest and pre‑arranged, suggesting low informational content for traders.

02

Market read

Limited relevance; likely no immediate price impact.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: filing posted on 2026-09-04, sale dated 2026-09-02

Background

Form 4 filings disclose insider transactions; director sales are monitored for potential signals.

Company-level read

Ticker impact

$AXGNNeutralMedium confidence
Context

Director Joseph Tyndall sold 3,500 shares of Axogen for $173,939.50 on 2026-09-02 via a 10b5‑1 plan.

Expected impact

Minimal short‑term price pressure; likely absorbed without significant move.

Evidence & confidence

The transaction size (~$174k) is low for a director and executed under a pre‑arranged plan, reducing informational value.

Market effects

None significant for the broader biotech sector.

No regional effect.

Limited to Axogen shareholders.

Counterpoint

The sale could be a routine liquidity event rather than a negative signal.

Key entities

  • Axogen, Inc.

    US‑listed biotech (NASDAQ: AXGN) developing nerve repair technologies.

  • Joseph Tyndall

    Director of Axogen executing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AXGNMedAI 8/10

Axogen Advances Prostate Market Launch, Citing $754 Million U.S. TAM

Axogen plans to launch a prostate-market product, targeting a $754M U.S. market. The company estimates 110,000 annual prostatectomy cases with a $7,000 per-procedure price. Axogen's COAPT technique, using Avance nerve allograft, has shown 80% of patients with better-than-expected erectile function after six months. 88% of surveyed patients expressed interest in the procedure.

$AXGNMed

Axogen Inc (AXGN) (Q3 2026) Earnings Call Highlights: Revenue Jumps 26% as Breast Market

Axogen Inc (AXGN) reported a 26% revenue increase in Q3 2026, driven by a 60% surge in the Breast market. CEO Michael Dale attributed growth to expanding commercial footprint and surgeon adoption. CFO Lindsay Hartley noted normal seasonality for Q4 growth. The company plans to target high-volume centers for robotic prostatectomies and expects continued growth in breast reconstruction. Gross margins for 2027 are expected to be similar to 2026, with no significant uplift anticipated.

$AXGNHighAI 8/10

AxoGen Q3 Earnings Call Highlights

AxoGen reported 96% commercial payer coverage for Avance Nerve Graft in the U.S. and updated clinical study results. It acquired BioCircuit for $200M, adding NerveTape to its portfolio. The company raised its 2026 revenue outlook to at least $290M, with organic growth of 26%. AxoGen plans to enter the prostate nerve reconstruction market in 2027.

$AXGNHigh

AxoGen, Inc. Q3 2026 Earnings Call Summary

Axogen reported Q3 2026 revenue growth of 26.2%, driven by Avance demand. Active accounts and surgeons increased significantly. The company achieved 96% U.S. commercial coverage. Acquired BioCircuit to enter the direct repair market. Raised 2026 revenue guidance to $290M. Gross margins expected to decline in Q4 due to production adjustments. BioCircuit acquisition is expected to be accretive to revenue and EBITDA margins. Prostate nerve reconstruction market development planned for 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.